{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T07:41:58Z","timestamp":1693208518549},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>Fibromyalgia (FM) is a chronic pain disorder for which pregabalin is an approved treatment in the United States. Although opioids are not a recommended treatment option, they continue to be used by many FM patients. The impact of patients\u2019 prior opioid use on their subsequent response to pregabalin has not been assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This was a pooled analysis of 4 clinical trials to assess the efficacy of pregabalin in FM patients both with and without prior opioid use. Patients were divided into those using opioids prior to the trial and those who were not. The change in least squares mean pain score (assessed by 0 to 10 numeric rating scale) with pregabalin compared with placebo was assessed together with FM symptoms, anxiety, and depression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>There were 2062 patients in the analysis set, including 371 patients with prior opioid use. Equal numbers of patients were treated with placebo, pregabalin 300 mg\/d, and pregabalin 450 mg\/d. Pregabalin significantly improved the least squares mean (95% confidence interval) difference in pain score compared with placebo in patients both with and without prior opioid use 0.87 (0.34-1.41) and 0.41 (0.17-0.65), respectively, at 300 mg\/d and 0.91 (0.39-1.44) and 0.72 (0.48-0.96) at 450 mg\/d (<jats:italic toggle=\"yes\">P<\/jats:italic>\u22640.001 for all). FM symptoms, anxiety, and depression were also improved with pregabalin compared with placebo, regardless of prior opioid use.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion:<\/jats:title>\n            <jats:p>FM patients respond to treatment with pregabalin with significant improvements in pain scores irrespective of prior opioid use. These data could inform treatment decisions for FM patients with prior use of opioids.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ajp.0000000000000232","type":"journal-article","created":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T08:48:42Z","timestamp":1426063722000},"page":"555-561","source":"Crossref","is-referenced-by-count":4,"title":["Prior Opioid Use Does Not Impact the Response to Pregabalin in Patients With Fibromyalgia"],"prefix":"10.1097","volume":"32","author":[{"given":"Charles E.","family":"Argoff","sequence":"first","affiliation":[{"name":"Albany Medical Center, Albany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Clair","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birol","family":"Emir","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ed","family":"Whalen","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Ortiz","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne","family":"Pauer","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, CT"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230827","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/art.1780330203","article-title":"The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee","volume":"33","author":"Wolfe","year":"1990","journal-title":"Arthritis Rheum"},{"key":"R2-20230827","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/acr.20140","article-title":"The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity","volume":"62","author":"Wolfe","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R3-20230827","first-page":"6","article-title":"Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment","volume":"75","author":"Mease","year":"2005","journal-title":"J Rheumatol Suppl"},{"key":"R5-20230827","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jpain.2008.03.013","article-title":"A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia","volume":"9","author":"Arnold","year":"2008","journal-title":"J Pain"},{"key":"R6-20230827","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/art.20983","article-title":"Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial","volume":"52","author":"Crofford","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R7-20230827","first-page":"502","article-title":"A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia","volume":"35","author":"Mease","year":"2008","journal-title":"J Rheumatol"},{"key":"R8-20230827","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.3899\/jrheum.110569","article-title":"An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia","volume":"38","author":"Pauer","year":"2011","journal-title":"J Rheumatol"},{"key":"R11-20230827","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/RHU.0b013e3182863447","article-title":"Chronic opioid use in fibromyalgia syndrome: a clinical review","volume":"19","author":"Painter","year":"2013","journal-title":"J Clin Rheumatol"},{"key":"R12-20230827","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1212\/WNL.0000000000000839","article-title":"Opioids for chronic noncancer pain: a position paper of the American Academy of Neurology","volume":"83","author":"Franklin","year":"2014","journal-title":"Neurology"},{"key":"R14-20230827","first-page":"CD010692","article-title":"Oxycodone for neuropathic pain and fibromyalgia in adults","volume":"6","author":"Gaskell","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R15-20230827","first-page":"898493","article-title":"Opioid use in fibromyalgia is associated with negative health related measures in a prospective cohort study","volume":"2013","author":"Fitzcharles","year":"2013","journal-title":"Pain Res Treat"},{"key":"R16-20230827","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.amjmed.2011.05.031","article-title":"Opioid use, misuse, and abuse in patients labeled as fibromyalgia","volume":"124","author":"Fitzcharles","year":"2011","journal-title":"Am J Med"},{"key":"R17-20230827","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1471-2474-8-27","article-title":"An internet survey of 2,596 people with fibromyalgia","volume":"8","author":"Bennett","year":"2007","journal-title":"BMC Musculoskelet Disord"},{"key":"R18-20230827","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1533-2500.2010.00412.x","article-title":"Comparison of medication adherence and healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia","volume":"11","author":"Zhao","year":"2011","journal-title":"Pain Pract"},{"key":"R19-20230827","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0002-9343(03)00116-5","article-title":"Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study","volume":"114","author":"Bennett","year":"2003","journal-title":"Am J Med"},{"key":"R20-20230827","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00124743-200010000-00004","article-title":"Efficacy of tramadol in treatment of pain in fibromyalgia","volume":"6","author":"Russell","year":"2000","journal-title":"J Clin Rheumatol"},{"key":"R21-20230827","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1001\/jama.292.19.2388","article-title":"Management of fibromyalgia syndrome","volume":"292","author":"Goldenberg","year":"2004","journal-title":"JAMA"},{"key":"R22-20230827","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations","volume":"9","author":"Dworkin","year":"2008","journal-title":"J Pain"},{"key":"R24-20230827","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1477-7525-1-29","article-title":"The Hospital Anxiety And Depression Scale","volume":"1","author":"Snaith","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"R25-20230827","first-page":"728","article-title":"The Fibromyalgia Impact Questionnaire: development and validation","volume":"18","author":"Burckhardt","year":"1991","journal-title":"J Rheumatol"},{"key":"R26-20230827","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/biomet\/63.3.581","article-title":"Inference and missing data","volume":"63","author":"Rubin","year":"1976","journal-title":"Biometrika"},{"key":"R27-20230827","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/01621459.1996.10476908","article-title":"Multiple imputation after 18+ years","volume":"91","author":"Rubin","year":"1996","journal-title":"J Am Stat Assoc"},{"key":"R28-20230827","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/ajgsup.2014.3","article-title":"The use of opioid analgesics for chronic pain: minimizing the risk for harm","volume":"2","author":"Argoff","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"R29-20230827","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/ard.2007.071522","article-title":"EULAR evidence-based recommendations for the management of fibromyalgia syndrome","volume":"67","author":"Carville","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R30-20230827","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/acr.22071","article-title":"Clinical characteristics and medication uses among fibromyalgia patients newly prescribed amitriptyline, duloxetine, gabapentin, or pregabalin","volume":"65","author":"Kim","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R31-20230827","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.clinthera.2013.02.003","article-title":"Geographic variation of chronic opioid use in fibromyalgia","volume":"35","author":"Painter","year":"2013","journal-title":"Clin Ther"},{"key":"R32-20230827","doi-asserted-by":"crossref","first-page":"479","DOI":"10.36076\/ppj.2007\/10\/479","article-title":"Opioid analgesia: perspectives on right use and utility","volume":"10","author":"Ballantyne","year":"2007","journal-title":"Pain Physician"},{"key":"R33-20230827","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/AJP.0b013e31816b2f43","article-title":"Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations","volume":"24","author":"Chu","year":"2008","journal-title":"Clin J Pain"},{"key":"R34-20230827","doi-asserted-by":"crossref","first-page":"10000","DOI":"10.1523\/JNEUROSCI.2849-07.2007","article-title":"Decreased central mu-opioid receptor availability in fibromyalgia","volume":"27","author":"Harris","year":"2007","journal-title":"J Neurosci"},{"key":"R35-20230827","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1056\/NEJMsr1203730","article-title":"The prevention and treatment of missing data in clinical trials","volume":"367","author":"Little","year":"2012","journal-title":"N Engl J Med"},{"key":"R37-20230827","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0033-3182(10)70741-6","article-title":"Relationships among pain and depressive and anxiety symptoms in clinical trials of pregabalin in fibromyalgia","volume":"51","author":"Arnold","year":"2010","journal-title":"Psychosomatics"},{"key":"R38-20230827","doi-asserted-by":"crossref","first-page":"R1046","DOI":"10.1186\/ar1782","article-title":"Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids","volume":"7","author":"Moore","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"R39-20230827","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/papr.12146","article-title":"A comprehensive drug safety evaluation of pregabalin in peripheral neuropathic pain","volume":"15","author":"Freynhagen","year":"2015","journal-title":"Pain Pract"}],"container-title":["The Clinical Journal of Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002508-201607000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T05:08:22Z","timestamp":1693112902000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002508-201607000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/ajp.0000000000000232","relation":{},"ISSN":["0749-8047"],"issn-type":[{"value":"0749-8047","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]}}}